ZA201704743B - Mangiferin-6-o-berberine salt and preparation method and use thereof - Google Patents

Mangiferin-6-o-berberine salt and preparation method and use thereof

Info

Publication number
ZA201704743B
ZA201704743B ZA2017/04743A ZA201704743A ZA201704743B ZA 201704743 B ZA201704743 B ZA 201704743B ZA 2017/04743 A ZA2017/04743 A ZA 2017/04743A ZA 201704743 A ZA201704743 A ZA 201704743A ZA 201704743 B ZA201704743 B ZA 201704743B
Authority
ZA
South Africa
Prior art keywords
mangiferin
preparation
berberine salt
berberine
salt
Prior art date
Application number
ZA2017/04743A
Inventor
Lin Zhe
Zhang Jingzhuo
Wu Wei
Teng Houlei
Original Assignee
Changzhou Deze Medical Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou Deze Medical Science Co Ltd filed Critical Changzhou Deze Medical Science Co Ltd
Publication of ZA201704743B publication Critical patent/ZA201704743B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
ZA2017/04743A 2015-01-07 2017-07-13 Mangiferin-6-o-berberine salt and preparation method and use thereof ZA201704743B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510005381 2015-01-07
PCT/CN2016/070229 WO2016110250A1 (en) 2015-01-07 2016-01-06 Mangiferin-6-o-berberine salt and preparation method and use thereof

Publications (1)

Publication Number Publication Date
ZA201704743B true ZA201704743B (en) 2018-12-19

Family

ID=56355531

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/04743A ZA201704743B (en) 2015-01-07 2017-07-13 Mangiferin-6-o-berberine salt and preparation method and use thereof

Country Status (11)

Country Link
US (1) US10285969B2 (en)
EP (1) EP3243823B1 (en)
JP (1) JP6460498B2 (en)
KR (1) KR101986983B1 (en)
CN (1) CN107108603B (en)
AU (1) AU2016206179B2 (en)
BR (1) BR112017014416A2 (en)
CA (1) CA2970561C (en)
RU (1) RU2670088C1 (en)
WO (1) WO2016110250A1 (en)
ZA (1) ZA201704743B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018006737A1 (en) * 2016-07-04 2018-01-11 常州德泽医药科技有限公司 Mangiferin-6-o-calcium salt and preparation method and use thereof
JP2019178070A (en) * 2018-03-30 2019-10-17 大正製薬株式会社 Mitol production promoter
CN108570046B (en) * 2018-05-31 2019-10-11 闽江学院 A kind of berberine-Chrysin pharmaceutical co-crystals and preparation method thereof
JP7185226B2 (en) * 2018-11-22 2022-12-07 国立大学法人 鹿児島大学 AMPK Activator Containing 1,5-Anhydrofructose Derivative
CN115414350B (en) * 2022-09-22 2023-08-04 湖北省农业科学院畜牧兽医研究所 Application of mangiferin in preparing medicine for inhibiting haemophilus parasuis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000042507A (en) * 1998-12-21 2000-07-15 박원배 5.,6-dihydrodibenzo(a,g)quinolizinium derivative having inhibition effect on bio-synthesis of cholesterol
CN101066275A (en) * 2007-06-12 2007-11-07 广西中医学院 Mangiferin-berberine composition
CN101921270A (en) * 2009-06-16 2010-12-22 海南德泽药物研究有限公司 Mangiferin berberine salt, preparation method thereof and use thereof
CN103816153A (en) * 2013-12-10 2014-05-28 无锡万全医药技术有限公司 Application of compound DZCY06 in preparation of drugs for treating diabetes

Also Published As

Publication number Publication date
US10285969B2 (en) 2019-05-14
RU2670088C1 (en) 2018-10-18
US20170273940A1 (en) 2017-09-28
JP6460498B2 (en) 2019-01-30
WO2016110250A1 (en) 2016-07-14
BR112017014416A2 (en) 2018-03-20
EP3243823A4 (en) 2018-07-18
AU2016206179B2 (en) 2018-08-02
EP3243823B1 (en) 2020-12-16
CN107108603A (en) 2017-08-29
AU2016206179A1 (en) 2017-07-06
EP3243823A1 (en) 2017-11-15
CN107108603B (en) 2019-06-07
KR20170092628A (en) 2017-08-11
CA2970561C (en) 2019-07-23
KR101986983B1 (en) 2019-06-07
CA2970561A1 (en) 2016-07-14
JP2018501293A (en) 2018-01-18

Similar Documents

Publication Publication Date Title
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
ZA201605154B (en) Insecticidal proteins and methods for their use
ZA201702161B (en) Insecticidal proteins and methods for their use
EP3338786C0 (en) Shenlingbaizhu granules and preparation method thereof
HK1253049A1 (en) Glycan-interacting compounds and methods of use
EP3159424A4 (en) Rebar and preparation method thereof
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
GB201514756D0 (en) Compound and method of use
GB201514760D0 (en) Compounds and method of use
HK1215280A1 (en) Saliva preserving solution and preparation method and use thereof
PL3398598T3 (en) Sulfonamide derivative and preparation method and use thereof
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
EP3235851A4 (en) Nylon salt and preparation method therefor
GB201520255D0 (en) Composition and method
HK1214767A1 (en) Tablet-formed pharmaceutical composition and preparation method thereof
EP3269710A4 (en) Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
PT3263133T (en) Pyridinone compound and use thereof
IL254597A0 (en) Crystalline form of ahu377, preparation method and use thereof
SI3349594T1 (en) Salt substitute composition and use thereof
GB201509420D0 (en) Composition and method
HRP20180716T1 (en) New ivabradine salt and its preparation process
IL253174A0 (en) Nanoparticles and methods for preparation thereof
GB201513492D0 (en) Method and composition
EP3479829A4 (en) Mangiferin-6-o-calcium salt and preparation method and use thereof
GB2545167B (en) Cloches and use thereof